| Symbol | RKVTF |
|---|---|
| Name | RAKOVINA THERAPEUTICS INC |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | - |
| Address | V5Z 1K5 Canada BC Suite 720, 999 West Broadway |
| Telephone | — |
| Fax | — |
| — | |
| Website | https://www.rakovinatherapeutics.com/ |
| Incorporation | — |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: TSX Venture Exchange |
| CIK | — |
| Description | Rakovina Therapeutics Inc. engages in the research and development of new cancer treatments based on novel series of small-molecule DNA-damage response inhibitors (DDRi). Its preclinical product pipeline include kt-2000, a next generation oral targeted small molecule PARP inhibitors; kt-3000, a bi-functional small-molecule drug candidate; and kt-4000, a DNA-damaging DDR inhibitors. Additional info from OTC: |
No news found.